Horizon accuses Actavis of infringing Vimovo patents

Horizon Pharma has filed a complaint against Actavis accusing it of infringing three of patents for the Vimovo (naproxen/esomeprazole magnesium) drug.

Vimovo is approved for relieving signs and symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and to decrease the risk of stomach ulcers.

The complaint, filed yesterday, August 11, at the US District Court for the District of New Jersey came after Actavis sought approval from the US Food and Drug Association to market a generic version of the drug.

Horizon said Actavis’s efforts to market a generic, including through filing an Abbreviated New Drug Application, infringe three patents covering Vimovo, US numbers 8,945,621; 9,220,698 and 9,345,695.

Horizon has asked the court for an injunction preventing Actavis from bringing their generic version of the drug to market prior to the expiration of its patents.